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Purpose: The aim of this study was to evaluate the efficacy and safety of naftopidil compared with tamsulosin in patients with 
neurogenic lower urinary tract dysfunction (LUTD).
Methods: This study was conducted as an 8-week, active-controlled, stratified-randomized, double-blind, double-dummy, 
parallel group, noninferiority, and multicenter clinical trial. After 2 weeks of screening, eligible subjects were randomly as-
signed to receive naftopidil (25 mg for 1 week followed by 75 mg for 7 weeks) or tamsulosin (0.2 mg for 8 weeks). Primary 
endpoint was a change of International Prostatic Symptom Score (IPSS) total score after 8 weeks of treatment.
Results: One hundred ninety-four subjects with neurogenic LUTD were included into this trial. There were no differences be-
tween the 2 groups in baseline characteristics, including urodynamic study results, subtype of LUTD, pretreatment and con-
comitant medication, and causes of neurogenic bladder. The medication compliance rate was 94.0% (naftopidil, 93.6%; tamsu-
losin, 94.4%). There was a statistically significant decrease of IPSS total score at 8 weeks versus baseline in both the naftopidil 
(-5.64±0.66) and tamsulosin (-6.53±0.65) groups (P<0.0001 each). The mean difference between both groups was 0.89 (up-
per limit of 95% confidential interval, 2.72), which was lower than the noninferiority limit of 3 points. A subgroup analysis of 
neurologic lesions and sex found no mean difference of IPSS total score in each group. There was also no difference in safety 
profiles, including treatment emergent adverse events.
Conclusions: Naftopidil was not inferior to tamsulosin as a therapeutic drug for patients with neurogenic LUTD and had a 
similar safety profile.
Keywords: Neurogenic; Lower urinary tract symptoms; Naftopidil; Urinary bladder
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INTRODUCTION
Neurogenic lower urinary tract dysfunction (LUTD) is com-
mon in patients with various neurological diseases. Alpha-
blockers have been shown to be effective treatments for im-
proving storage symptoms as well as voiding symptoms in neu-
rogenic LUTD [1,2]. Alpha1a-adrenergic receptors (ARs) pre-
dominate in the human prostate; blockade relaxes prostatic 
smooth muscle and increases urine flow [3], and α1d-ARs pre-
dominate in human detrusor, spinal cord, and afferent nerves, 
where blockade decreases LUTD symptoms. Thus, α1-AR act 
not only directly on the smooth muscle, but also on the spinal 
cord, ganglion and nerve endings affecting sympathetic and 
parasympathetic nerves [4]. Alpha1-blockers have been shown 
to reduce urinary tract resistance in patients with neurogenic 
LUTD and are effective in the treatment of voiding dysfunc-
tion, even in female patients [5].
 Naftopidil was also reported to be effective on both symp-
toms and urodynamic variables of patients with neurogenic 
LUTD in a noncomparative, single-arm study [6]. Naftopidil is 
reported to have a 3-fold higher affinity for α1D-AR than α1A-
AR, while tamsulosin and silodosin have much more affinity for 
α1A-AR than α1D-AR [7,8]. Naftopidil appears to have similar 
effects on urological symptom scores and quality of life (QoL) 
compared to tamsulosin and silodosin in patients with nonneu-
rogenic LUTD, such as benign prostatic hyperplasia [9]. Cur-
rently marketed α-blockers, including naftopidil, are being pre-
scribed in patients with neurogenic LUTD in several countries. 
However, the clinical effects of naftopidil on neurogenic LUTD 
have been rarely reported. Therefore, we evaluated the efficacy 
and safety of naftopidil in patients with neurogenic LUTD.
MATERIALS AND METHODS
This study was conducted as an 8-week, active-controlled, strati-
fied-randomized, double-blind, double-dummy, parallel group, 
noninferiority, and 15-multicenter clinical trial. The internal re-
view board of each center approved this trial and written informed 
consent was obtained from all participants before screening. This 
study was registered in ClinicalTrials.gov (NCT02034604). The 
screening period was up to 2 weeks and the double-blind treat-
ment period was 8 weeks.
 This trial consisted of screening (visit 1), random assignment 
(visit 2), and follow-up at week 4 (visit 3), and week 8 (visit 4). 
After the screening test, eligible subjects were randomly as-
signed to 1 of 2 treatment groups (naftopidil or tamsulosin) by 
institution and sex at a ratio of 1:1. Subjects received either 25 
mg of naftopidil for 1 week followed by 75 mg of naftopidil for 
7 weeks, or 0.2 mg of tamsulosin for 8 weeks. International 
Prostatic Symptom Score (IPSS), uroflowmetry and postvoid 
residual (PVR) were conducted at screening visits 1, 3, and 4. 
Voiding diary was assessed at visits 2, 3, and 4, and the subject 
surveys (Benefit, Satisfaction, and Willingness to Continue 
Questionnaire [BSW-Q] [10], Global Response Assessment for 
Koreans [GRA-K], and Treatment Satisfaction Questionnaire 
[TSQ]) were administered at visits 3 and 4. The GRA measures 
the overall improvement with therapy. The assessment asks: “As 
compared to when you started the current study (treatment), 
how would you rate your overall lower urinary tract symptoms 
now?”. The patient was provided with the following 7 response 
options: markedly worse, moderately worse, slightly worse, no 
change, slightly improved, moderately improved, and markedly 
improved. The TSQ was rated on a 5-point scale, participant 
was asked: “overall how satisfied are you with your medica-
tion?”: very satisfied, somewhat satisfied, neither dissatisfied 
nor satisfied, somewhat dissatisfied, and very dissatisfied.
Inclusion and Exclusion Criteria
Qualified researchers confirmed and documented inclusion 
criteria for each patient. Inclusion and exclusion criteria are 
shown in Supplementary material 1.
Assessment
The aim of this trial was to evaluate the efficacy and safety of 
naftopidil compared to tamsulosin in patients with neurogenic 
LUTD. The primary endpoint of efficacy was to compare the 
change of IPSS total score (excluding QoL) after 8 weeks of 
treatment versus baseline. A secondary endpoint of efficacy was 
based on changes in baseline values for the following tests: uro-
flowmetry with PVR, IPSS subdomain, and QoL score, urinary 
frequency and nocturia, BSW-Q, GRA-K, and TSQ. Safety end-
points consisted of treatment emergent adverse events (TEAEs), 
adverse drug reactions (ADRs), and serious AE/ADR. All ad-
verse events were classified according to WHO Adverse Reac-
tion Terminology (WHO-ART092).
Statistical Methods
The change in the 8-week IPSS total score versus baseline was 
projected to be approximately 8 to 9 in the 2 treatment groups 
and the standard deviation was projected to be approximately 7. 
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The noninferiority limit of naftopidil for tamsulosin was defined 
as 3, which was assumed to maintain about 60%–70% of the 
tamsulosin effect regarding the change in 8-week IPSS total 
score versus baseline. Under this assumption, the sample size for 
the evaluation of noninferiority at 80% power and 2.5% one-
sided significance level was 172 cases, i.e., 86 cases per treatment 
group. A total of 204 subjects were recruited with 102 cases per 
treatment group considering a 15% dropout rate. For primary 
endpoint, to demonstrate noninferiority of naftopidil to tamsu-
losin, if the upper limit of 2-sided 95% confidence interval (CI) 
for differences in least square means between 2 treatment 
groups (naftopidil-tamsulosin) calculated using an analysis of 
covariance (ANCOVA) model in which baseline values were 
used as a covariate was less than noninferiority margin of 3 
points, then naftopidil was considered to be noninferior to tam-
sulosin. For efficacy assessment, an ANCOVA model with base-
line values as a covariate was used to compare the endpoints be-
tween treatment groups for continuous data and the chi-square 
test or Fisher exact test was used for categorical data. For safety 
assessment, frequencies and percentages of subjects who experi-
enced AEs were summarized and the difference of incidence 
rate between treatment groups was compared using the chi-
square test or Fisher exact test. Statistical analysis was performed 
using the SAS ver. 9.2 (SAS Institute, Cary, NC, USA).
RESULTS
Baseline characteristics of the 194 subjects enrolled in this trial 
Table 1. Baseline characteristics (intent-to-treat set)   
Characteristic Tamsulosin (n=99) Naftopidil (n=95) P-value
Age (yr) 59.07±10.77 61.11±12.29 0.097
Male sex 37 (37.37) 35 (36.84) 0.939
Height (cm) 159.25±8.61 159.44±8.41 0.764
Weight (kg) 60.64±9.35 59.86±8.72 0.552
Urodynamic study
   Qmax (mL/sec)
   PdetQmax (cm H2O)
   BOOI
















Lower urinary tract symptoms       
Storage symptoms
   Frequency
   Nocturia
   Urgency













   Weak stream
   Splitting
   Intermittency
   Hesitancy
   Straining

















   Dribbling








Others 2 (2.02) 5 (5.26) 0.272
Location of neurogenic causes
   Brain
   Spinal cord
   Periphery
















Values are presented as mean±standard deviation or number (%).   
Qmax, maximum flow rate; PdetQmax, detrusor pressure at maximum flow rate; BOOI, bladder outlet obstruction index; BCI, bladder contractility index.
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are presented in Table 1. There were no differences between the 
2 groups in pretreatment characteristics such as urodynamic 
study results, type of LUTS, and causes of neurogenic bladder. 
The medication compliance rate was 94.0% for the entire study 
group, 93.6% for the naftopidil group, and 94.4% for the tamsu-
losin group, for a total of 194 patients included in the intent-to-
treat set consisted of all randomized subjects.
 Of the 194 randomized subjects (95 naftopidil and 99 tamsu-
losin), 181 (89 naftopidil and 92 tamsulosin) who received at 
least one dose of clinical trial medication and could be evaluat-
ed for the primary efficacy endpoint after randomization were 
included in the full-analysis (FA) set. The safety analysis group 
was defined as at least one dose of the clinical trial drug and 
one or more safety-related evaluations by telephone or visit af-
ter drug administration. Of the 194 randomly assigned subjects, 
189 who received a clinical trial drug (92 naftopidil and 97 tam-
sulosin) were included in the safety analysis group, excluding 5 
(3 naftopidil, 2 tamsulosin) (Fig. 1).
 Both groups showed a statistically significant decrease in the 
FA set of IPSS total score at 8 weeks (mean change of the naf-
topidil group, -5.64±0.66; tamsulosin group, -6.53±0.65, re-
spectively, P<0.0001). The mean difference between both groups 
was 0.89, and upper limit of 95% CI for the difference between 
the 2 groups was 2.72, which was lower than the noninferiority 
limit of 3 points. Therefore, compared with tamsulosin, naftopi-
dil was found to be noninferior  in IPSS total score change at 8 
weeks (Table 2).
 For secondary endpoints, all variables of uroflowmetry and 
PVR parameters (Table 3), IPSS subdomain and QoL score (Fig. 
2), urinary frequency and nocturia (Fig. 3) at 4 and 8 weeks were 
not significantly different between the tamsulosin and naftopidil 
groups. There were also no differences between groups at 8 
weeks in the BSW-Q, GRA-K, and TSQ. There were significant 
differences between the tamsulosin and naftopidil groups in the 
response distribution of the GRA-K (P=0.0318) and TSQ (P= 






















Fig. 1. Flow chart of the study. A/E, adverse events; C/W, consent withdrawal; F/U, follow-up. a)C/W: n=1; Violation: n=1. b)C/W: 
n=2; Others: n=1.
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Table 3. Uroflowmetry and PVR evaluation between the tamsulosin and naftopidil groups
Variable Tamsulosin (n=92) Naftopidil (n=89) P-value
Qmax
   Change from baseline at week 4 3.18±0.74* 2.15±0.74* 0.326
   Change from baseline at week 8 4.00±0.78* 3.22±0.79* 0.487
Qmean
   Change from baseline at week 4 1.34±0.35* 0.40±0.35 0.058
   Change from baseline at week 8 1.55±0.34* 0.85±0.35* 0.146
PVR
   Change from baseline at week 4 -21.46±5.47* -28.87±5.54* 0.343
   Change from baseline at week 8 -16.20±6.16* -16.90±6.23* 0.936
Voided volume
   Change from baseline at week 4 5.47±14.82 -24.28±14.82 0.159
   Change from baseline at week 8 2.90±13.98 7.99±14.22 0.799
PVR/(voided volume + PVR)×100%
   Change from baseline at week 4 -2.28±2.10 -2.16±2.09 0.968
   Change from baseline at week 8 -4.21±1.67* -1.98±1.69 0.350
Values are presented as mean±standard error.
PVR, postvoid residual; Qmax, maximum flow rate; Qmean, mean flow rate; ANCOVA, analysis of covariance. 
*P<0.05, difference between baseline and postbaseline (ANCOVA using baseline value as covariate).
Table 2. Change from baseline in IPSS total score (full analysis set)
Variable Tamsulosin (n=92) Naftopidil (n=89)
Baseline 21.67±5.69 22.06±5.93
Week 4 16.61±6.01 17.60±6.20
Week 8 15.26±6.74 16.30±6.57
Change from baseline at week 4a) -5.14±0.53 -4.38±0.54
   P-value <0.001 <0.001
Change from baseline at week 8a) -6.53±0.65 -5.64±0.66
   P-value <0.001 <0.001
Tamsulosin vs. naftopidil
   Difference between mean change 0.89
   95% CI for the differenceb) (-0.95–2.72)
IPSS, International Prostatic Symptom Score; CI, confidence interval; ANCOVA, analysis of covariance.
a)Difference between baseline and postbaseline in each group (ANCOVA using baseline value as covariate). b)Difference between treatment groups 
(ANCOVA using baseline value as covariate). 
 The subgroup analysis of neurologic lesions showed that 
there was no mean difference (naftopidil group - tamsulosin 
group) in IPSS total score change at 8 weeks between the 2 
treatment groups. The mean difference of IPSS total score was 
-0.79 (95% CI, -6.02 to 4.43) in subjects with brain lesions, 0.63 
(-1.86 to 3.13) in subjects with spinal cord problems, and 2.51 
(-1.16 to 6.17) in subjects with peripheral nervous disease. 
There was no difference between the 2 groups according to sex. 
The mean difference of the IPSS total score change at 8 weeks 
between the 2 treatment groups was -0.36 (-3.52 to 2.81) for 
male subjects and 1.51 (-0.81 to 3.84) for female subjects.
 During the trial, 97 TEAEs occurred in 57 subjects (30.16%) 
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of the 189 subjects for safety analysis set, including 27 subjects 
(29.35%, 42 cases) in the naftopidil group and 30 subjects 
(30.93%, 55 cases) in the tamsulosin group, and there was no 
difference of incidence rate between the treatment groups (P= 
0.8130). Eleven serious AEs occurred in 9 subjects (4.76%), 2 
with naftopidil (2.17%, 4 cases), and 7 with tamsulosin (7.22%, 
7 cases). There was no difference of incidence rate of serious 
AEs between the treatment groups (P=0.1705). Five AEs that 
resulted in temporary discontinuation of the medication oc-
curred in 2 subjects (1.06%), 1 in the naftopidil group (1.09%, 2 
cases), and 1 in the tamsulosin group (1.03%, 3 cases). There 
was no difference of incidence rate of AEs which resulted in 
temporary discontinuation of the medication between the 
treatment groups (P=1.0000). Three patients (3.26%, 6 cases) 
in the naftopidil group and 7 patients (7.22%, 10 cases) in the 
tamsulosin group needed to discontinue medication perma-
Fig. 2. Change from baseline to 4 and 8 weeks in International Prostatic Symptom Score (IPSS) and quality of life (QoL) score. *Statis-















































































Fig. 3. Change from baseline to 4 and 8 weeks in urinary frequency and nocturia. *Statistically significant change from baseline. NS, 
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nently (P=0.3322). No AE-related death was reported during 
this trial. ADRs are shown in Table 4. Ten ADR cases that re-
sulted in permanent discontinuation of the drug were reported 
in 7 patients, including dyspepsia (n=1) and nausea (n=1) in 
the naftopidil group, and urinary incontinence (n=2), urinary 
frequency (n =1), abdominal pain (n =1), dizziness (n =1), 
tremor (n=1), pruritus (n=1), and skin rash (n=1) in the tam-
sulosin group. Of these, all of the ADRs that resulted in perma-
nent discontinuation of naftopidil were mild or moderate, and 
all resolved without sequelae except urinary incontinence (n=1), 
urinary frequency (n=1) in the tamsulosin group. There were 
no AEs that resulted in serious ADRs or death in this trial, and 
no other specific finding was found in other safety profiles. 
Therefore, it was confirmed that the safety profile of naftopidil 
did not differ from that of tamsulosin.
DISCUSSION
The aim of this trial was to evaluate the efficacy and safety of 
naftopidil in patients with neurogenic LUTS. After 8 weeks of 
administration, both the naftopidil and tamsulosin groups 
showed statistically significant improvement in the primary ef-
ficacy variable of total IPSS, and naftopidil was not inferior to 
tamsulosin in terms of improved total IPSS. In addition, there 
was no significant difference between the tamsulosin and naf-
topidil groups in all variables at 4 and 8 weeks in uroflowmetry 
and PVR changes or questionnaires about urinary symptom 
changes. There were significant differences between the tamsu-
losin and naftopidil groups in the GRA-K (P=0.0318) and TSQ 
(P=0.0095) at 4 weeks. However, when the results were subdi-
vided into 3 categories (improvement, no change, or deteriora-
tion for the GRA-K, and satisfaction, no satisfaction and no 
dissatisfaction, or dissatisfaction for the TSQ), there was no dif-
ference between the groups even at 4 weeks.
 Alpha-blockers may play an important role in improving 
emptying by decreasing outlet resistance in neurogenic LUTD. 
Alpha-blockers decrease PVR and increase urinary flow rate in 
patients with a neurogenic bladder [11,12]. Kakizaki et al. [11] 
reported that tamsulosin reduces functional urethral resistance 
during voiding and improves the flow rate in patients with a 
neurogenic bladder. Alpha-blockers have also been shown to 
decrease detrusor overactivity on urodynamic studies [13] and 
have beneficial effects on storage symptoms [14]. In patients 
with a neurogenic bladder and poor bladder compliance, com-
bination medical therapy including α-blockers significantly im-
proves compliance, decreases bladder pressure at capacity and 
improves clinical outcomes compared to single antimuscarinic 
therapy [15,16]. Collectively, α-blockers have some modest ef-
fects in patients with a neurogenic bladder in facilitation of 
voiding, but also serve to increase capacity and compliance in 
combination with anticholinergics [17]. In addition, α-blockers 
have some effects on preventing serious harm from autonomic 
dysreflexia [2,12,18]. Krum et al. [19] reported that α-blockers 
significantly decrease the magnitude of hypertension and sever-
ity of secondary symptoms during autonomic dysreflexia trig-
gered by a variety of iatrogenic stimuli.
 Although α-blockers have shown some clinical effects on 
neurogenic bladders, the precise mechanisms of action are still 
unknown. Abrams et al. [1] found that tamsulosin decreases 
maximum urethral pressure in patients with neurogenic LUTD. 
Bladder outlet obstruction can be reduced by a decrease in the 
maximum urethral pressure in patients with spinal cord injury 
Table 4. Overall summary of adverse drug reactions during clinical trial
Variable Tamsulosin (n=97) Naftopidil (n=92) P-value
Subject with ADRs (cases) 10 (17) 5 (7) 0.2153
Severity
   Mild 10 4
   Moderate 7 3
   Severe 0 0
Subjects with serious ADRs 0 0
Subjects with ADRs Leading to temporarily discontinuation (cases) 1 (2) 0 1.000
Subjects with ADRs leading to permanently discontinuation (cases) 5 (8) 2 (2) 0.445
Subjects with ADRs leading to death 0 0
ADRs, adverse drug reactions.
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(SCI) [20]. Regarding the expression of α1-ARs in the human 
spinal cord, α1AR mRNA is predominantly present in ventral 
gray matter (ventral>dorsal; sacral>lumbar=thoracic>cervic
al), while α1D-AR is the predominant receptor subtype overall 
[21]. Traditionally, α1D-ARs are known to be mainly expressed 
in the bladder detrusor, with higher mRNA expression than 
that of α1A-Ars [22,23]. Thus, α1D-ARs are believed to be 
closely involved in storage symptoms. In a recent report using a 
decerebrated rat model with SCI, Ishida et al. [24] measured 
sphincter electromyography activity and demonstrated that 
naftopidil increased voiding efficiency by reducing external 
urethral sphincter resistance, while silodosin did not affect any 
parameters. The authors concluded that α1D-AR plays an im-
portant role in maintaining external urethral sphincter activity 
in the spinal cord, and α1D-blockade may influence the activity 
of Onuf ’s nuclei motor neurons, resulting in a decrease in ex-
ternal urethral sphincter tone.
 Despite these data, the clinical effects of naftopidil on neuro-
genic LUTD have been rarely reported. A Japanese naftopidil 
neurogenic LUTD study group demonstrated that naftopidil 
has a significant effect on both symptoms and urodynamic 
variables of patients of both sexes with neurogenic LUTD [6]. 
They also found that PVR<300 mL and bladder contractility 
are predictive factors for the efficacy of naftopidil. Theirs was 
the first report regarding the effect of naftopidil in neurogenic 
LUTD, although it was not a comparative study. In the current 
study, naftopidil improved subjective symptoms and objective 
findings in patients with neurogenic LUTD, and its effects were 
not inferior to those of tamsulosin. These results were effective 
regardless of sex or neurological causes. To our best knowledge, 
this is the first randomized controlled study to compare naftop-
idil and the other subtype of α1-blockers (e.g., tamsulosin) in 
neurogenic LUTD.
 This study has several limitations. First, when managing 
neurogenic LUTD in real clinical practice, it is much more 
common to use a combination of medications including anti-
cholinergics and β3-agonist than α-blockers alone. The trial 
treatment strategy may not fit well with actual clinical situa-
tions. Second, there was no evaluation of long-term outcomes, 
given the follow-up period of only 8 weeks. Although the fol-
low-up period was short, it was considered sufficient to com-
pare the effects and side effects of the 2 drugs.
 In conclusion, this clinical trial demonstrated that naftopidil 
was not inferior to tamsulosin as a therapeutic drug for patients 
with neurogenic LUTD. Naftopidil had a safety profile similar 
to tamsulosin and should be considered as a safe drug that can 
improve symptoms in patients with neurogenic LUTD.
SUPPLEMENTARY MATERIAL
Supplementary material 1 can be found via https://doi.org/ 
10.5213/inj.1938198.099.
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